Drug Safety System Will Be Improved By Medicare Rx, HHS Secretary Tells PhRMA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Part D benefit will allow HHS to gather useful postmarketing data to help improve the regulation of drug safety, Leavitt says. The HHS Secretary dowplays the need for legislative changes at FDA.
You may also be interested in...
FDA Advisory Committees To Help Decide Medicare Rx Data Research Agenda
Claims data collected on prescriptions filled through the Medicare drug benefit will be used by outside groups to produce evidence on drugs' safety and effectiveness. FDA advisory committees, AHRQ and IoM could help determine study priorities, CMS says.
FDA Advisory Committees To Help Decide Medicare Rx Data Research Agenda
Claims data collected on prescriptions filled through the Medicare drug benefit will be used by outside groups to produce evidence on drugs' safety and effectiveness. FDA advisory committees, AHRQ and IoM could help determine study priorities, CMS says.
FDA Drug Safety Oversight Board Will Include VA, Other Agencies
The panel is the primary feature of FDA's proposal to reform drug safety review within the agency; other features include the creation of a drug safety website. The panel and website are intended to increase drug safety "oversight" and "openness" at FDA.